Bristol-myers Squibb Compnay

Guohua Zhao

Pratik Devasthale

Wei Meng

Saleem Ahmad

R Michael Lawrence

Jon J Hangeland

Robert Paul Brigance

Huji Turdi

Kumaravel Selvakumar

Suresh Dhanusu

William N Washburn

James Mignone

William A Slusarchyk

Michael Frederick Parker

Manoranjan Panda

Lawrence R Marcin

Xiang-Yang Ye

Rita Civiello

Uwe D Treuner

Dean A Wacker

Gregory S Bisacchi

Xiaojun Han

Swanee E Jacutin-Porte

Leatte R Guernon

Fang Moore

Susan Nicole Pieniazek

Palanikumar Balasubramanian

Yan Shi

James Clifford Sutton

Ramesh Kumar Sistla

Shung C Wu

Philip D Stein

Susheel Jethanand Nara

Yanting Huang

Srinivas Cheruku

Andres S Hernandez

Wei Wang

Daniel L Cheney

Elizabeth Anne Jurica

David S Yoon

Dong Cheng

Rushith Kumar Anumula

Ximao Wu

Rishikesh Narayan

Jeffrey G Varnes

Steven M Seiler

Chet Kwon

James C Sutton, Jr

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The disclosure relates to compounds of formula I: Formula I which inhibit &#x3b1;-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. 

Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Cyclobutane- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

The present invention provides compounds of Formula (I): 

Bridged bicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Pyrrole amides as alpha V integrin inhibitors

Dihydropyridinone MGAT2 inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments. 

Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments. 

Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists

Growing community of inventors

Princeton, NJ, United States of America

Guohua Zhao